$8.18
At close: Apr 16 EDT
$8.18
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
OptimizeRx Analyst Ratings and Price Targets | NASDAQ:OPRX | Benzinga
OptimizeRx Corp has a consensus price target of $20.04 based on the ratings of 12 analysts. The high is $66 issued by Roth Capital on May 5, 2022. The low is $5 issued by Barclays on November 14, 2024. The 3 most-recent analyst ratings were released by JMP Securities, RBC Capital, and Lake Street on February 6, 2025, January 8, 2025, and December 24, 2024, respectively. With an average price target of $8.33 between JMP Securities, RBC Capital, and Lake Street, there's an implied 1.87% upside for OptimizeRx Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
RBC Capital
Lake Street
B. Riley Securities
Stephens & Co.
1calculated from analyst ratings
Analyst Ratings for OptimizeRx
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/06/2025 | Buy Now | -2.2% | JMP Securities | Constantine Davides37% | $8 → $8 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/08/2025 | Buy Now | -26.65% | RBC Capital | Sean Dodge48% | $7 → $6 | Downgrade | Outperform → Sector Perform | Get Alert |
| 12/24/2024 | Buy Now | 34.47% | Lake Street | Eric Martinuzzi49% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 12/24/2024 | Buy Now | 58.92% | B. Riley Securities | Neil Chatterji35% | $17 → $13 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | -32.76% | Stephens & Co. | Jeff Garro40% | → $5.5 | Initiates | → Equal-Weight | Get Alert |
| 11/14/2024 | Buy Now | -2.2% | JMP Securities | Constantine Davides37% | $16 → $8 | Maintains | Market Outperform | Get Alert |
| 11/14/2024 | Buy Now | -14.43% | RBC Capital | Sean Dodge48% | $14 → $7 | Maintains | Outperform | Get Alert |
| 11/14/2024 | Buy Now | 95.6% | Roth MKM | Richard Baldry38% | $20 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | -2.2% | Stifel | David Grossman63% | $13 → $8 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | -38.88% | Barclays | Stephanie Davis41% | $11 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/16/2024 | Buy Now | 71.15% | RBC Capital | Sean Dodge48% | $17 → $14 | Maintains | Outperform | Get Alert |
| 08/12/2024 | Buy Now | 34.47% | Barclays | Stephanie Davis41% | $15 → $11 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | 95.6% | JMP Securities | Constantine Davides37% | $16 → $16 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/21/2024 | Buy Now | 95.6% | JMP Securities | Constantine Davides37% | $16 → $16 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | 95.6% | JMP Securities | Constantine Davides37% | $15 → $16 | Maintains | Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | 58.92% | Stifel | David Grossman63% | $13 → $13 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 83.37% | JMP Securities | Constantine Davides37% | $15 → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/04/2024 | Buy Now | 83.37% | JMP Securities | Constantine Davides37% | → $15 | Initiates | → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | 107.82% | RBC Capital | Sean Dodge48% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 04/01/2024 | Buy Now | 58.92% | Stifel | David Grossman63% | $13 → $13 | Maintains | Buy | Get Alert |
| 01/10/2024 | Buy Now | 107.82% | RBC Capital | Sean Dodge48% | $14 → $17 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | 83.37% | Barclays | Stephanie Davis41% | → $15 | Initiates | → Equal-Weight | Get Alert |
| 08/15/2023 | Buy Now | 71.15% | RBC Capital | Sean Dodge48% | $18 → $14 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 58.92% | Lake Street | Eric Martinuzzi49% | $18 → $13 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 144.5% | Roth MKM | Richard Baldry38% | $31 → $20 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 120.05% | B. Riley Securities | Neil Chatterji35% | $28 → $18 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 58.92% | Stifel | David Grossman63% | $16 → $13 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | 120.05% | RBC Capital | Sean Dodge48% | $22 → $18 | Maintains | Outperform | Get Alert |
| 02/02/2023 | Buy Now | 266.75% | B. Riley Securities | Neil Chatterji35% | → $30 | Reinstates | → Buy | Get Alert |
| 11/01/2022 | Buy Now | 132.27% | Stifel | David Grossman63% | → $19 | Initiates | → Buy | Get Alert |
| 10/31/2022 | Buy Now | 132.27% | Stifel | David Grossman63% | → $19 | Initiates | → Buy | Get Alert |
| 08/10/2022 | Buy Now | 168.95% | RBC Capital | Sean Dodge48% | $50 → $22 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 95.6% | Piper Sandler | Jeff Garro40% | $29 → $16 | Maintains | Neutral | Get Alert |
| 08/10/2022 | Buy Now | 266.75% | SVB Leerink | Joy Zhang26% | $38 → $30 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | 584.6% | B. Riley Securities | Marc Wiesenberger75% | $71 → $56 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 364.55% | SVB Leerink | Joy Zhang26% | → $38 | Initiates | → Outperform | Get Alert |
| 07/01/2022 | Buy Now | 254.52% | Piper Sandler | Jeff Garro40% | → $29 | Initiates | → Neutral | Get Alert |
| 05/05/2022 | Buy Now | 511.25% | RBC Capital | Sean Dodge48% | $100 → $50 | Maintains | Outperform | Get Alert |
| 05/05/2022 | Buy Now | 706.85% | Roth Capital | Richard Baldry38% | $112 → $66 | Maintains | Buy | Get Alert |
FAQ
What is the target price for OptimizeRx (OPRX) stock?
The latest price target for OptimizeRx (NASDAQ:OPRX) was reported by JMP Securities on February 6, 2025. The analyst firm set a price target for $8.00 expecting OPRX to fall to within 12 months (a possible -2.20% downside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OptimizeRx (OPRX)?
The latest analyst rating for OptimizeRx (NASDAQ:OPRX) was provided by JMP Securities, and OptimizeRx reiterated their market outperform rating.
When was the last upgrade for OptimizeRx (OPRX)?
There is no last upgrade for OptimizeRx
When was the last downgrade for OptimizeRx (OPRX)?
The last downgrade for OptimizeRx Corp happened on January 8, 2025 when RBC Capital changed their price target from $7 to $6 for OptimizeRx Corp.
When is the next analyst rating going to be posted or updated for OptimizeRx (OPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OptimizeRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OptimizeRx was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.
Is the Analyst Rating OptimizeRx (OPRX) correct?
While ratings are subjective and will change, the latest OptimizeRx (OPRX) rating was a reiterated with a price target of $8.00 to $8.00. The current price OptimizeRx (OPRX) is trading at is $8.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
